Hyderabad: Hyderabad-based pharmaceutical company Dr Reddy’s on Friday said it hopes to submit phase 3 trial data of Sputnik V Light, the single dose vaccine, to the Drugs Controller General of India (DCGI) next month. The company is also starting trials on children in two cohorts involving children of the age groups of 2-12 years […]
Hyderabad: Bharat Biotech completed the Phase 2/3 trials of Covid-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella said on Tuesday here. Speaking to reporters, he said Covaxin […]
Hyderabad: Hyderabad-based Hetero Group said that the Drug Controller General of India (DCGI) has issued Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India for the treatment of Covid-19 in hospitalised adults. It is aimed to treat individuals who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical […]
Developed by the DRDO, 2-DG has been granted permission by Drug Controller General of India for emergency use as adjunct therapy in moderate to severe Covid-19 patients.
Hyderabad-based pharma company has approached the Drug Controller General of India to seek Emergency Use Authorization for the investigational drug in India
The Companies manufacturing COVID-19 vaccination in India have given only "Emergency Use Authorization for vaccinating people of 18 years age and above
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO).
Covid-19 drug candidate has been developed by VINS Bioproducts in collaboration with Centre for Cellular and Molecular Biology and University of Hyderabad
